Rgenta Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 Tradecenter Ste 6600, Woburn, Massac...Phone Number
(781) 608-3996Website
www.rgentatx.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Rgenta Therapeutics
Founded in 2018, headquartered in Cambridge, Massachusetts, Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. The company's proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. The company's lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.Explore more
Rgenta Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rgenta Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Rgenta Therapeutics
Earning: See what the market has to say on Rgenta Therapeutics recently announced quarterly report
Product Launch: Get notified when Rgenta Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Rgenta Therapeutics has new funding data
Click to see if Rgenta Therapeutics had a recent Job posting/layoffs
Rgenta Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Rgenta Therapeutics is spiking on competitors!
Check if Rgenta Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Rgenta Therapeutics
Compare insights from companies similar to Rgenta Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
-
2000
JH
Jun HayashiPresident of Precision Antibody, Vice President of A & G Pharmaceutical Inc
Company Profile Activity
Activity Insights
Rgenta Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Rgenta Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Rgenta Therapeutics.
Rgenta Therapeutics financials insights
Gather financial insights about Rgenta Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$18M
2022
Series A
$52M
Rgenta Therapeutics Tech Stack
A closer look at the technologies used by Rgenta Therapeutics
Most Recent Scoops
Project
Product Development, Product Management, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Event
Product Marketing, Events, Sales, Food & Beverage, Hospitality, Field /Outside Sales, Field Marketing
Executive Move
Board of Directors
Event
Events
Funding
Rgenta Therapeutics News & Media
Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that two abstracts highlighting preclinical data from its proprietary RSwitch technology, which enables the fine-tuning of transgene levels in gene and cell therapy applications, have been accepted for oral presentation at the AmericaRgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that an abstract highlighting clinical data from the ongoing Phase 1a/b study of RGT-61159, an oral MYB splicing modulator, in patients with adenoid cystic carcinoma (ACC) or colorectal cancer (CRC) has been accepted for poster presenRgenta Therapeutics Presents Preclinical Data, Unveiling its New Drug Candidate, RGT-0474060, as a Promising Oral PMS1 Inhibitor for the Treatment of Huntington’s Disease
WOBURN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that preclinical data from its new Huntington’s disease (HD) drug candidate targeting PMS1, RGT-0474060, were presented at the 21st Annual HD Therapeutics Conference being held this week in Palm Springs, CA. The data, generated in a moRgenta Therapeutics Receives Orphan Drug Designation from the U.S. FDA for RGT-61159 for the Treatment of Adenoid Cystic Carcinoma (ACC)
RGT-61159 is being evaluated in an ongoing multi-center, Phase 1a/b clinical trial in patients with advanced relapsed or refractory ACC RGT-61159 is being evaluated in an ongoing multi-center, Phase 1a/b clinical trial in patients with advanced relapsed or refractory ACC
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rgenta Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2018, headquartered in Cambridge, Massachusetts, Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. The company's proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecu... Read More
